The treatment and study of systemic sclerosis (SSc) is entering a new era with the reporting and preparation of several randomized controlled trials according to an improved understanding of SSc pathogenesis. Advances in trial designs reported in 2014 should now be built upon with further improvements to patient selection to enable targeting of therapies to specific subgroups of patients with SSc.
References
Cobo-Ibáñez, T. et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin. Arthritis Rheum. http://dx.doi.org/10.1016/j.semarthrit.2014.04.002.
Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 6, 498–506 (2011).
van Laar, J. M. et al. EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 25, 2490–2498 (2014).
Nihtyanova, S. I. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum. 66, 1625–1635 (2014).
Elhai, M., Meune, C., Avouac, J., Kahan, A. & Allanore, Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 51, 1017–1026 (2012).
Nikpour, M. & Baron, M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr. Opin. Rheumatol. 26, 131–137 (2014).
Clements, P. J. et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 42, 1194–1203 (1999).
Nagaraja, V., Denton, C. P. & Khanna, D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) http://dx.doi.org/10.1093/rheumatology/keu285.
Maurer, B. et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-205226.
Merkel, P. A. et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 64, 3420–3429 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Y.A. declares that he has received honoraria or research grants from Actelion, Bayer, Inventiva, Medac, Pfizer, Roche/Genentech, Sanofi and Servier. O.D. declares that he has consulted for, or has received research funding from, 4D Science, Actelion, Active Biotec, Bayer-Schering, Biogen, Biovitrium, BMS, Boehringer Ingelheim Pharma, EpiPharm, Ergonex, GSK, Inventiva, Medac, Novartis, Pfizer, Roche/Genentech, Sanofi/Genzyme, Serodapharm, Sinoxa and United BioSource Corporation.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Allanore, Y., Distler, O. Advances in cohort enrichment shape future of trial design. Nat Rev Rheumatol 11, 72–74 (2015). https://doi.org/10.1038/nrrheum.2014.222
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2014.222
- Springer Nature Limited
This article is cited by
-
Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay
Arthritis Research & Therapy (2018)
-
Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine
Stem Cell Research & Therapy (2017)
-
Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes
Arthritis Research & Therapy (2017)
-
Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study
Arthritis Research & Therapy (2016)
-
Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy
Seminars in Immunopathology (2016)